Skip to content

Insider · CIK 0001536908

Sujata Tyagi Dayal

director

Files at EBS (Emergent BioSolutions Inc.). First filing Nov 10, 2025, latest Nov 10, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $86k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

EBS: Emergent BioSolutions Inc.

EBSOct 9, 2026 · close 7.06

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
12Weak
EBSsell 210b5-1
Emergent BioSolutions Inc.
$86k
8,552 shares
-9%+139% from low-21% from high

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Nov 7, 2025EBS
Emergent BioSolutions Inc.
SOpen-market sale
Common Stock10b5-1
-8,552$10.00$86k88,980Nov 10, 2025
Apr 30, 2025EBS
Emergent BioSolutions Inc.
AGrant or award
Common Stock
+34,403$0.00$097,532May 2, 2025
Apr 30, 2025EBS
Emergent BioSolutions Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+15,824$0.00$041,572May 2, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Sujata Tyagi Dayal: insider trades and track record | InsiderTell